S10.7 · Food, Agriculture & Beverage
A pharma-margin animal health market where AI-assisted diagnostics is challenging the specialist veterinarian's referral role.
Global animal health is roughly a $55-60B market (2024, Grand View Research and comparable estimates, 2025), growing high-single-digit annually — faster than human pharmaceutical growth rates — on companion-animal spending and livestock-productivity demand. The highest-margin lines carry pharma-like economics, and that is where the segment's value concentrates. It is also where AI is pressing most directly on a licensed professional's diagnostic role, through AI-assisted imaging and pathology.
R&D and manufacturing concentrate in the US, Germany and France; demand is global, though companion-animal spending sits mostly in developed markets. Four companies hold roughly half the global market between them: Zoetis (~$9B revenue), Boehringer Ingelheim Animal Health, Merck Animal Health (~$6B) and Elanco (~$4.4B). The remainder fragments among Ceva, Virbac and a long tail of regional players.
The segment sits downstream of pharmaceutical and biotech R&D and upstream of veterinarians, livestock producers and feed companies. Its economics split cleanly by end market, and the split is the analysis. Companion-animal and vaccine lines carry pharma-like margins and meaningful IP protection. Livestock and feed-additive lines run at lower margin and closer to the commodity-exposed end of the spectrum — much closer, in fact, to the economics of the livestock-production segment they serve than to companion-animal medicine. Animal feed and nutrition additives form a separate market adjacent to, but outside, this figure; it is larger in aggregate spend and more commodity-adjacent in its pricing, which is why it is tracked as a distinct pool of demand rather than folded into the animal-health total.
Diagnostics bolt-ons — point-of-care veterinary testing platforms — change the revenue model, not just the product line: a diagnostic device sold into a clinic throws off a recurring stream of consumables and testing revenue rather than a one-time hardware sale, which is why the major animal-health companies want them. Feed-additive integration by producers runs the other way — margin protection against input-cost volatility, not a bet on new revenue.
The AI effect concentrated in this segment is on diagnostic interpretation. AI-assisted imaging and pathology tools can now read routine diagnostic cases — a portion of the work that has historically required a specialist veterinarian's referral and interpretation — at a fraction of the cost and turnaround time. The referral moat specialist vets have held for routine cases erodes; complex or ambiguous presentations, where clinical judgment still matters, stay with the specialist. AI diagnostics are already in commercial use in companion-animal care, where testing volumes and willingness to pay are highest. Rollout at livestock scale, where per-animal value is lower and deploying diagnostic AI pencils less obviously, is more likely 2-5 years out.